clonoSEQ is the 1st U. S. Food and Drug Administration (FDA) cleared MRD test for Multiple Myeloma, Chronic Lymphoblastic Leukaemia (CLL), and B-Acute Lymphoblastic Leukaemia (B-ALL). clonoSEQ is a highly sensitive NGS based assay which is increasingly becoming the standard practices in patient management.
The National Medical Commission has agreed to make significant changes to the draft post-graduate medical education regulations 2021 bill, which proposed a common counselling for all the institutions on the basis of national rankings. Minimum stipend for junior residents has not fixed. Several doctors’ bodies,
The hematological cancer therapy market is diverse and highly genericized, with chemotherapies currently accounting for the highest number of marketed drugs. However, the availability of more targeted and innovative therapies means that sales of antibodies, cell therapies and targeted therapies are all set to increase